Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CicloMulsion Trial Failure Leaves NeuroVive Dependent On NeuroSTAT

Executive Summary

NeuroVive of Sweden pulled the plug on its lead cyclophilin inhibitor after it showed no benefit in preventing acute kidney injury in patients treated with the therapy prior to open heart surgery – but the specialty pharma says it has other early assets to concentrate on now.


Related Content

Cellvation Tackling Traumatic Brain Injuries With Stem Cell Therapy


Related Companies